More importantly, tumor‐localized inflammation is concurrently reduced, as evidenced by decreased levels of pro‐inflammatory factors, including TNF‐α and IL‐6, in tumor tissues at the end of the therapeutic period. This evidence concerns the gene TNF and neoplasm.